Britain and America have announced a significant trade agreement that will ensure zero tariffs on UK medicine shipments going into the American market.
The Terms of the Pact
Under the terms of the agreement, the UK has pledged to boost spending on pharmaceuticals through the National Health Service (NHS). This commitment secures that tariffs on these key exports will stay at zero for a timeframe of the next three years.
This development is in response to recent threats to dramatically increase duties on patented drug imports, with figures floated as high as 100%.
"This agreement with the United Kingdom strengthens the global environment for innovative medicines and introduces much-needed balance to transatlantic pharmaceutical trade," a release declared.
Economic Importance
Medicines constitute one of the the United Kingdom's largest goods shipped to the United States, which is by far the largest destination for major British pharmaceutical firms.
Statistics reveal that in the 12 months prior to last September, the UK exported medicines totaling over eleven billion pounds to the US. This figure made up 17.4% of all goods exports in that span.
"This deal safeguards work, stimulates funding and sets the stage for the UK to become a international leader for biotech and pharma," the Business and Trade Secretary stated.
Key NHS Changes
The pact entails several notable pledges from the UK:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it considers new therapies to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a goal to increase overall health service expenditure on medicines from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Payback Limit: The amount pharmaceutical firms must return to the NHS to prevent overspending will be restricted at 15%. In the past, repayments exceeded 20%.
Recent Tensions
The deal follows a long-running row between the sector and the British authorities over spending levels and regulatory access.
The disagreement were heightened by arguments that American customers were paying several times more for the same drugs than patients in the Britain and the EU.
Recently, several significant manufacturing plans in the UK have been halted or scrapped, while substantial funding commitments have been directed toward American operations.
One official publicly accepted that the NHS must spend more on treatments, noting that its budget allocation on drugs had decreased as a percentage of its overall budget over the last ten years.
